Skip to main content

Table 1 This is a comprehensive list of all the studies that included the Nuss procedure

From: Systematic review of surgical treatment techniques for adult and pediatric patients with pectus excavatum

Reference n Study type Follow-up (years) Age, mean (range), years Operation duration, min Analgesia duration, epidural/ IV, days Mean blood loss, mL Mean LOS, days Outcome, >good/ excellent, % Non-displacement complication/ self-resolving, % Requiring reoperation, % Bar displacement, % Number of bars removed, % Symptoms Lung function Cardiac function
Esteves [[35]] a 19 R   22.6 (20–27) 96.5 3/--   6.1   0/--    21    
Teh [[36]] 19 R 2.4 (.3-5.9) 19.5 (17–42) 126 3/--   5.8   42/31 10.5 10.5 32    
Cheng [[37]] b 96 P 1.8 (0.4 - 3.0) 24.5 (18–42) 80 c   <10 7.2 92/73 3/1 2 2 7    
Hebra [[38]] 30 R   23 (18–32)   3/--   6 86/50 20/4   6.7     
Aronson [[39]] 35    23 (18–47) 65 c (4–5)/--   7 c   34/--   14.3 40    
Schalamon [[40]] b 43 P 1.9 (0.5 - 5) 22 (18–39) 70    9.3 --/91 23/-- 0 2.3 35   Same  
Kim [[32]] 12 R 3.4 27 (20–52) 127.3    10 64/-- 58/-- 42 8.3     
Coln [[41]] 8 R 1.8 (19–32) 92 2.8/<5   4   100/50 0 25 50 Better   Better
Zganjer [42] 128 R 3.6 13.8 (8–21)   --/4 35 10 95/73d 41/20 4.7 4.7 42 Better   Better
Esteves [35]a 26 R   15.3 (5.0-19) 90.3 3/--   5.07   4/--    12    
Nuri [43] 12 R 3.6 (0.3 - 7) 9 (4.0-21)        0 33.3     
Densmore [44] 117 R 4 12.9 (8.0-18) 118 --/3.8 <10 5.8   21/-- 16 12 100    
Mao [45] 115 R   7.9 (2.7-18) 59.5 --/5.1   8.5 98/90 20/6 1.7 2.6 32    
Felts [46] 25   2.2 13.8 (5.0-18)   3/--   7 96/-- 20/-- 4 4 52   Better  
Lam [25] 19 R   15.4 (13–18) 72.1 3.7/--   4.5         
Sigalet [47] 26 P >2 13.2     5    11.5 11.5   Better Better Same
Kubiak [48] 15    15.9 (10.7-18.1)       33/20 6.7 13.3    Better Better
Kelly [24]a,b 284 P 0.2 13.6 (8.0-21)      97/90 98/47   2.5     
Coln [49]a 123 R <2 13 (5.0-18)   --/2.9   3.1   11/--   0.8   Better   Better
Aronson [39] 141    13 (5.0-17) 65c    7c   24/-- 0.7 12.8 55    
Kim [32] 39 R 3.4 8.9 (1.5-19) 60.7    5.9 83/-- 25/-- 7.7 5.1     
Bohosiewicz [50] 66 R   11.8 (1.0-19)      --/85 15/-- 1.5   36    
Watanabe [51] 53 R   9 (4.0-18) 76 --/4.3 4 8.9   26/2 3.8 7.5     
Ohno [33] 23 R   7.6 (3.0-19) 143.5   16.5 7.9 --/78 13/--   8.7     
Inge [30] 43 R 1.4 (0.6 - 2.8) 11 (4–19) 70 0/--   2.4 90/ 14/-- 4.7 4.7     
Fonkalsrud [34] 68 R   12 (5.0-19) 75 3/5 90 6.5   13/-- 10.2 8.8 26    
Molik [27] 35 R   9.5 (5.0-20) 198 3/3.8   4.8   37/-- 22.9 17.1     
Miller [29] 80 R   9.4 (<21) 53   20 3.7 95/-- 45/8 5 5 20 Better   
Engum [52] 20 R 1.2 (0.2-1.6) 8.2 (5–15)     4.9   40/35 15 20     
Nuss [21] 42 R 4.6 (1–9.2) (<15)    15 4.3 87/73d 24/7 4.8 4.8     
  1. The table is divided horizontally with bold & plain text to differentiate between pediatric and adult patients. Within each subgroup studies are organized in reverse chronological order from top to bottom based on publication date.
  2. a= >3% patients reported to have Marfans.
  3. b = >20% of patients reported to have scoliosis.
  4. c = Median (not included in weighted averages).
  5. d = specified as long-term outcomes.
  6. P/R = Prospective/Retrospective Cohort Study.